MX2022009018A - Nanoparticulas lipidas. - Google Patents
Nanoparticulas lipidas.Info
- Publication number
- MX2022009018A MX2022009018A MX2022009018A MX2022009018A MX2022009018A MX 2022009018 A MX2022009018 A MX 2022009018A MX 2022009018 A MX2022009018 A MX 2022009018A MX 2022009018 A MX2022009018 A MX 2022009018A MX 2022009018 A MX2022009018 A MX 2022009018A
- Authority
- MX
- Mexico
- Prior art keywords
- lnp
- lipid
- present
- lipid nanoparticles
- specifically
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930182558 Sterol Natural products 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20152995 | 2020-01-21 | ||
| EP20152938 | 2020-01-21 | ||
| EP20179434 | 2020-06-11 | ||
| PCT/EP2021/051290 WO2021148511A1 (en) | 2020-01-21 | 2021-01-21 | Lipid nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009018A true MX2022009018A (es) | 2022-08-11 |
Family
ID=74215945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009018A MX2022009018A (es) | 2020-01-21 | 2021-01-21 | Nanoparticulas lipidas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230067722A1 (https=) |
| EP (1) | EP4093373A1 (https=) |
| JP (1) | JP2023517275A (https=) |
| KR (1) | KR20230002300A (https=) |
| CN (1) | CN115697298A (https=) |
| AU (1) | AU2021211894A1 (https=) |
| BR (1) | BR112022013837A2 (https=) |
| CA (1) | CA3168696A1 (https=) |
| IL (1) | IL294624A (https=) |
| MX (1) | MX2022009018A (https=) |
| TW (1) | TW202139975A (https=) |
| WO (1) | WO2021148511A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020182993A1 (en) * | 2019-03-13 | 2020-09-17 | Etherna Immunotherapies Nv | Mrna vaccine |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| EP4346901A4 (en) * | 2021-06-01 | 2025-04-23 | The University of British Columbia | MRNA DELIVERY USING LIPID NANOPARTICLES |
| CA3238764A1 (en) * | 2021-11-23 | 2023-06-01 | Siddharth Patel | A bacteria-derived lipid composition and use thereof |
| CN114716355B (zh) * | 2022-04-02 | 2023-09-05 | 华南理工大学 | 一种脂质化合物、包含其的组合物及应用 |
| CN115887674B (zh) * | 2022-04-29 | 2023-08-25 | 北京剂泰医药科技有限公司 | 脂质纳米颗粒 |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| CN115414476B (zh) * | 2022-08-15 | 2023-07-14 | 珠海暨创硒源纳米科技有限公司 | 一种改性氧化镁、含镁纳米颗粒水溶液及其制备方法与在制备佐剂中的应用 |
| WO2024064206A1 (en) * | 2022-09-20 | 2024-03-28 | Emory University | Lipid nanoparticles comprising nucleic acids encoding therapeutic genes and uses in medical methods |
| CN116763756A (zh) * | 2022-10-11 | 2023-09-19 | 中国科学院化学研究所 | 一种脂质纳米颗粒及其制备方法和应用 |
| JP7813825B2 (ja) * | 2023-02-07 | 2026-02-13 | 株式会社微生物化学研究所 | ワクチン |
| CN115998714B (zh) * | 2023-03-20 | 2023-06-30 | 威瑞生物科技(昆明)有限责任公司 | 一种脂质纳米颗粒、递送系统及递送系统的制备方法 |
| EP4442256A1 (en) | 2023-04-04 | 2024-10-09 | Københavns Universitet | Lipid nanoparticle compositions |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117159492A (zh) * | 2023-07-27 | 2023-12-05 | 广州制高点医药科技有限公司 | 一种含有唾液酸脂质衍生物的脂质纳米颗粒及其应用 |
| CN120359024A (zh) | 2023-10-12 | 2025-07-22 | 科百博生物股份有限公司 | 脂质纳米颗粒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110305769A1 (en) * | 2008-11-17 | 2011-12-15 | Enzon Pharmaceuticals, Inc. | Branched cationic lipids for nucleic acids delivery system |
| EP3243504A1 (en) * | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| KR101766408B1 (ko) * | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| ES2795110T3 (es) * | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| AU2014340149B2 (en) * | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| HUE058792T2 (hu) | 2013-11-12 | 2022-09-28 | Univ Brussel Vrije | RNS-transzkripciós vektor és felhasználása |
| EP3247398A4 (en) * | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| PL3386484T3 (pl) * | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| US11458106B2 (en) * | 2016-05-09 | 2022-10-04 | Astrazeneca Ab | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof |
| WO2017218704A1 (en) * | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CN109563511A (zh) * | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
| WO2018175783A1 (en) * | 2017-03-22 | 2018-09-27 | Modernatx, Inc. | Rna bacterial vaccines |
| EP3733647B1 (en) * | 2017-12-27 | 2022-06-15 | Eisai R&D Management Co., Ltd. | Cationic lipid |
| CA3088485A1 (en) * | 2018-01-18 | 2019-07-25 | Etherna Immunotherapies Nv | Lipid nanoparticles |
-
2021
- 2021-01-21 EP EP21701492.7A patent/EP4093373A1/en active Pending
- 2021-01-21 BR BR112022013837A patent/BR112022013837A2/pt unknown
- 2021-01-21 IL IL294624A patent/IL294624A/en unknown
- 2021-01-21 TW TW110102316A patent/TW202139975A/zh unknown
- 2021-01-21 US US17/794,087 patent/US20230067722A1/en active Pending
- 2021-01-21 JP JP2022544069A patent/JP2023517275A/ja active Pending
- 2021-01-21 CA CA3168696A patent/CA3168696A1/en active Pending
- 2021-01-21 CN CN202180010449.4A patent/CN115697298A/zh active Pending
- 2021-01-21 AU AU2021211894A patent/AU2021211894A1/en active Pending
- 2021-01-21 KR KR1020227028916A patent/KR20230002300A/ko active Pending
- 2021-01-21 MX MX2022009018A patent/MX2022009018A/es unknown
- 2021-01-21 WO PCT/EP2021/051290 patent/WO2021148511A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4093373A1 (en) | 2022-11-30 |
| BR112022013837A2 (pt) | 2022-09-13 |
| AU2021211894A1 (en) | 2022-09-01 |
| US20230067722A1 (en) | 2023-03-02 |
| TW202139975A (zh) | 2021-11-01 |
| WO2021148511A1 (en) | 2021-07-29 |
| JP2023517275A (ja) | 2023-04-25 |
| CA3168696A1 (en) | 2021-07-29 |
| KR20230002300A (ko) | 2023-01-05 |
| IL294624A (en) | 2022-09-01 |
| CN115697298A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009018A (es) | Nanoparticulas lipidas. | |
| ZA202300131B (en) | Lipid nanoparticles | |
| Liang et al. | Development and delivery systems of mRNA vaccines | |
| Gote et al. | A comprehensive review of mRNA vaccines | |
| Barbier et al. | The clinical progress of mRNA vaccines and immunotherapies | |
| Aldosari et al. | Lipid nanoparticles as delivery systems for RNA-based vaccines | |
| Huang et al. | The landscape of mRNA nanomedicine | |
| Pardi et al. | Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes | |
| Yan et al. | Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| MX2023004371A (es) | Lípidos ionizables, y métodos de fabricación y uso de los mismos. | |
| US11235069B2 (en) | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo | |
| JP6703982B2 (ja) | 脂質およびリポソームの安定な製剤 | |
| WO2017173453A1 (en) | Stimuli-responsive nanoparticles for biomedical applications | |
| CA3172600A1 (en) | Rna particles comprising polysarcosine | |
| MX2023014901A (es) | Nanoparticulas que contienen acido nucleico. | |
| MX2025010536A (es) | Nuevas formulaciones de nanoparticulas lipidicas para la administracion de acidos nucleicos | |
| Wang et al. | Advances in the study of LNPs for mRNA delivery and clinical applications | |
| de Moura et al. | Enhancing the effect of nucleic acid vaccines in the treatment of HPV-related cancers: an overview of delivery systems | |
| Gao et al. | Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy | |
| EP4721733A1 (en) | Nucleic acid-lipid nanoparticle composition, and lyophilized preparation thereof, preparation method therefor and use thereof | |
| Aldosari et al. | Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics 2021, 13, 206 | |
| Wu et al. | Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024; 12 (2): 186 | |
| CN117088820B (zh) | 一种新型阳离子lnp递送系统及制备方法 | |
| Du et al. | The rise of mRNA therapeutic vaccines |